GlassScriptPhysician profile
Jin Moon Kang
NPI 1083651194
$3,687.44
in general payments reported to CMS, 2019-2025
22 companies · $901 in 2025
The $901 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $87.64 · 2023: $993 · 2024: $1,134 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.31 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $700.10 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $537.75 | 2019-2025 | |
| Astellas Pharma US INC | $428.96 | 2023-2025 | Veozah |
| Amgen INC. | $301.17 | 2019-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $223.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $220.50 | 2023-2025 | Mitraclip, Navitor |
| Lilly USA, LLC | $200.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $170.04 | 2019-2025 | |
| Abbvie INC. | $147.75 | 2023-2025 | |
| Dexcom, INC. | $134.07 | 2024 | Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $104.32 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $89.06 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $88.05 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Optinose US, INC. | $87.64 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.09 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $49.52 | 2023-2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $38.17 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $32.27 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.29 | 2025 | Jardiance |
| Jazz Pharmaceuticals INC. | $20.06 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.80 | 2023 | Quviviq |
| Seqirus USA INC | $14.13 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Moon Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.